Jason R Pantarotto

List of Publications by Year
in descending order

27	1,163	840119 11	642321 23
papers	citations	h-index	g-index

28	28	28	1642
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cancer Clinic Redesign: Opportunities for Resource Optimization. Current Oncology, 2022, 29, 3983-3995.	0.9	0
2	Validating impact of pretreatment tumor growth rate on outcome of earlyâ€stage lung cancer treated with stereotactic body radiation therapy. Thoracic Cancer, 2021, 12, 201-209.	0.8	3
3	Radiation oncologist consultations prior to prostatectomy in Ontario, Canada: Disparities and opportunities.. Journal of Clinical Oncology, 2021, 39, e17052-e17052.	0.8	0
4	Adrenal oligometastasis cured with stereotactic ablative radiotherapy. Radiology Case Reports, 2020, 15, 2266-2270.	0.2	2
5	Anemia is a poor prognostic factor for stage I non-small cell lung cancer (NSCLC) patients treated with Stereotactic Body Radiation Therapy (SBRT). Clinical and Translational Radiation Oncology, 2019, 16, 28-33.	0.9	7
6	Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Nonâ€“Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. Journal of Clinical Oncology, 2019, 37, 1316-1325.	0.8	336
7	Clinical Specialist Radiation Therapist in Palliative Radiation Therapy: Report of an Orientation, Training, and Support Program. Journal of Medical Imaging and Radiation Sciences, 2019, 50, 543-550.	0.2	16
8	A Phase II Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-Field Boost Radiotherapy for Brain Oligometastases. Cureus, 2019, 11, e6394.	0.2	2
9	Radical Treatment of Stage II Nonâ€“small-cell Lung Cancer With Nonsurgical Approaches: A Multi-institution Report of Outcomes. Clinical Lung Cancer, 2018, 19, e11-e18.	1.1	6
10	Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncology, The, 2017, 18, 1116-1125.	5.1	415
11	Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer. Clinical and Translational Radiation Oncology, 2017, 5, 37-41.	0.9	4
12	Quantitative texture analysis on pre-treatment computed tomography predicts local recurrence in stage I non-small cell lung cancer following stereotactic radiation therapy. Quantitative Imaging in Medicine and Surgery, 2017, 7, 614-622.	1.1	12
13	Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1â€“3 metastases. Journal of Neuro-Oncology, 2016, 128, 431-436.	1.4	1
14	Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists. Lung Cancer, 2016, 94, 74-80.	0.9	7
15	Lung cancer diagnosis transformation: Aligning the people, processes, and technology sides of the learning system.. Journal of Clinical Oncology, 2016, 34, 50-50.	0.8	1
16	Pretreatment [18F]-fluoro-2-deoxy-glucose Positron Emission Tomography Maximum Standardized Uptake Value as Predictor of Distant Metastasis in Early-Stage Non-Small Cell Lung Cancer Treated With Definitive Radiation Therapy: Rethinking the Role of Positron Emission Tomography in Personalizing Treatment Based on Risk Status. International Journal of Radiation Oncology Biology Physics, 2014, 88, 312-318.	0.4	35
17	Prognostic Factors in the Radical Nonsurgical Treatment of Stage IIIB Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 237-243.	1.1	13
18	Upper abdominal normal organ contouring guidelines and atlas: A Radiation Therapy Oncology Group consensus. Practical Radiation Oncology, 2014, 4, 82-89.	1.1	103

#	Article	IF	Citations
19	Treatment of metastatic liver tumors using stereotactic ablative radiotherapy. World Journal of Radiology, 2014, 6, 18.	0.5	15
20	Phase II study of neoadjuvant irinotecan, capecitabine, oxaliplatin (IXO) followed by chemoradiotherapy (CRT) using concurrent capecitabine for resectable locally advanced rectal cancer.. Journal of Clinical Oncology, 2014, 32, e14571-e14571.	0.8	0
21	Stage II non-small cell lung cancer treated with nonsurgical approaches.. Journal of Clinical Oncology, 2014, 32, e18507-e18507.	0.8	0
22	Impact of Patient Selection, Disease Progression, and Adverse Events on Esophageal Cancer Outcomes After Trimodality Therapy. Annals of Thoracic Surgery, 2012, 94, 1659-1666.	0.7	10
23	Clinical use of a novel in vivo 4D monitoring system for simultaneous patient motion and dose measurements. Radiotherapy and Oncology, 2012, 102, 290-296.	0.3	15
24	Inferring Positions of Tumor and Nodes in Stage III Lung Cancer From Multiple Anatomical Surrogates Using Four-Dimensional Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1553-1560.	0.4	8
25	Motion Analysis of 100 Mediastinal Lymph Nodes: Potential Pitfalls in Treatment Planning and Adaptive Strategies. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1092-1099.	0.4	59
26	Role of Adaptive Radiotherapy During Concomitant Chemoradiotherapy for Lung Cancer: Analysis of Data From a Prospective Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1092-1097.	0.4	32
27	Smoking is associated with worse outcomes in patients with prostate cancer treated by radical radiotherapy. BJU International, 2007, 99, 564-569.	1.3	61